Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katherine Monti"'
Autor:
Elizabeth E. Kim, Benjamin Solomon, Keith D. Wilner, Yiyun Tang, Sai-Hong Ignatius Ou, Katherine Monti, Maria Winter, Sherry C. Wang
Publikováno v:
Lung Cancer. 145:167-172
Objectives During crizotinib clinical evaluation, visual disturbances, generally of grade 1 severity, were frequently reported adverse events (AE). Consequently, ophthalmologic assessments were included in a patient subgroup enrolled in PROFILE 1001
Autor:
Katherine Montiel Lugo
Publikováno v:
Revista Franz Tamayo, Vol 5, Iss 13, Pp 47-62 (2023)
Es fundamental analizar el sistema educativo, el contexto escolar, los planes curriculares y la exploración de enfoques y estrategias pedagógicas que aborden los procesos de selección de la literatura en la dinámica de la enseñanza y el aprendiz
Externí odkaz:
https://doaj.org/article/bebe1a84cd994c12ba10454808b8c082
Autor:
Jennifer Canniff, Amy S. Paller, Katherine Monti, Brett Jepson, Jon M. Hanifin, Donald Y.M. Leung, Gloria David, Adriana Weinberg, Lynda C. Schneider, Margarita Gomez Lorenzo, Lisa A. Beck
Publikováno v:
The Journal of allergy and clinical immunology. 139(5)
Background Antibody responses to the inactivated seasonal influenza vaccine in patients with atopic dermatitis (AD) have not been carefully characterized. Objective The primary objective of this study was to compare antibody responses to intradermal
Autor:
A. Drilon, Paul K. Paik, Sai-Hong Ou, Jared Weiss, Geoffrey I. Shapiro, Sherry C. Wang, Benjamin Solomon, Rebecca S. Heist, Katherine Monti, Gregory J. Riely, Keith D. Wilner, Mark A. Socinski, Maria Winter, D. Ross Camidge, Jeffrey W. Clark
Publikováno v:
Journal of Thoracic Oncology. 12:S438-S439
Autor:
Sai-Hong Ignatius Ou, Jeffrey W. Clark, Jared Weiss, D. Ross Camidge, Paul K. Paik, Mark A. Socinski, Alexander Drilon, Gregory J. Riely, Sherry C. Wang, Maria Winter, Keith D. Wilner, Katherine Monti
Publikováno v:
Journal of Clinical Oncology. 34:108-108
108Background: MET alterations leading to exon 14 skipping occur in ~4% of lung carcinomas, resulting in MET activation and sensitivity to MET inhibitors in vitro. Crizotinib, initially developed as a MET inhibitor, is currently approved for the trea